Of late, the exports have shifted in favour of regulated markets evidently as there has been an increase in the share of these markets to about 49% in 2013-14 from about 43% in 2008-09, the Assocham-Yes Bank joint study said.
"India's bulk drug exports are likely to grow at a CAGR of 12-14% till 2018-19, driven largely by exports to regulated markets," The Associated Chambers of Commerce and Industry of India added.
The study also said that the domestic formulations market is likely to cross $20 billion mark by 2018-19 from a level of about $11 billion in 2013-14.
"The growth story of domestic formulations market is expected to remain strong, led by better healthcare diagnostic infrastructure," it added.
)